Recent Quotes (30 days)

You have no recent quotes
chg | %

Nuvo Research Inc  

(Public, TSE:NRI)   Watch this stock  
Find more results for NRI
+0.11 (1.57%)
Oct 6 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 6.99 - 7.12
52 week 3.81 - 10.36
Open 7.05
Vol / Avg. 15,675.00/37,892.00
Mkt cap 77.86M
P/E 1.94
Div/yield     -
EPS 3.66
Shares 10.97M
Beta 0.28
Inst. own     -
Nov 9, 2015
Q3 2015 Nuvo Research Inc Earnings Release (Estimated) Add to calendar
Sep 9, 2015
Nuvo Research Inc at Rodman & Renshaw Global Investment Conference
Aug 5, 2015
Q2 2015 Nuvo Research Inc Earnings Release

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin -183.36% 295.55%
Operating margin -183.09% 280.74%
EBITD margin - -97.81%
Return on average assets -39.83% 88.96%
Return on average equity -45.26% 113.73%
Employees 66 -
CDP Score - -


7560 Airport Rd Unit 10
+1-905-6736980 (Phone)
+1-905-6731842 (Fax)

Website links


Nuvo Research Inc. (Nuvo) is a Canada-based pharmaceutical company, which operates two business units: the Topical Products and Technology (TPT) Group and the Immunology Group. The TPT Group has four commercial products, a pipeline of topical and transdermal drug delivery (TTDD) products, focusing on various therapeutic areas, including pain and dermatology and multiple drug delivery platforms that support the development of formulations that can deliver actives into or through the skin. The Immunology Group has two commercial products and an immune system modulation platform that supports the development of drug products that modulate chronic inflammation processes of various diseases. TPT Group's products include Pennsaid, Pennsaid 2%, Synera, Pliaglis, Rapydan and Heated Lidocaine/Tetracaine Patch.

Officers and directors

Daniel H. Chicoine Chairman of the Board, Co-Chief Executive Officer
John C. London President, Co-Chief Executive Officer, Director
Stephen L. Lemieux Chief Financial Officer, Vice President
Henrich R. K. Guntermann M.D. President of Europe and Immunology Group, Director
Katina Loucaides Vice President, General Counsel, Secretary
David A. Copeland Lead Independent Director
Anthony E. Dobranowski Independent Director
Jacques Messier Independent Director
Theodore H. Stanley M.D. Independent Director
Age: 74
Klaus von Lindeiner Independent Director